Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020095215 - CHEMICAL COMPOUNDS

Publication Number WO/2020/095215
Publication Date 14.05.2020
International Application No. PCT/IB2019/059517
International Filing Date 06.11.2019
IPC
C07D 417/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 417/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
C07D 421/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
421Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 491/048 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
044with only one oxygen atom as ring hetero atom in the oxygen-containing ring
048the oxygen-containing ring being five-membered
C07D 491/107 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
107with only one oxygen atom as ring hetero atom in the oxygen-containing ring
CPC
A61P 21/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
C07D 417/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 417/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
14containing three or more hetero rings
C07D 421/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
421Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 491/048
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
044with only one oxygen atom as ring hetero atom in the oxygen-containing ring
048the oxygen-containing ring being five-membered
C07D 491/107
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
107with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Applicants
  • GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED [GB]/[GB]
Inventors
  • CADILLA, Rodolfo
  • DEATON, David Norman
  • LARKIN, Andrew L
  • SCHULTE, Christie
  • SMALLEY JR, Terrence L.
Agents
  • HILLIER, Mark
Priority Data
62/757,20508.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CHEMICAL COMPOUNDS
(FR) COMPOSÉS CHIMIQUES
Abstract
(EN)
A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
(FR)
L'invention concerne un composé de formule (I), dans laquelle Ar1, R21, R23, R24, R25, R26, R27, A, X, Y et W sont tels que définis dans la description. Les composés selon la présente invention sont des inhibiteurs de la prostaglandine D synthase hématopoïétique (H-PGDS) et peuvent être utiles dans le traitement de la dystrophie musculaire de Duchenne. Par conséquent, l'invention concerne en outre des compositions pharmaceutiques comprenant un composé selon l'invention. La présente invention concerne par ailleurs des procédés d’inhibition de l’activité de H-PGDS et de traitement de troubles associés à cette activité, au moyen d'un composé selon l’invention ou d'une composition pharmaceutique comprenant un composé selon l’invention.
Latest bibliographic data on file with the International Bureau